SLSheldon S. Leung

Sheldon S. Leung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sheldon S. Leung has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents

    by Petr O Ilyinskii, Christopher Roy, Alicia Michaud, Gina Rizzo, Teresa Capela, Sheldon S Leung, Takashi Kei Kishimoto

    Tolerogenic ImmTOR nanoparticles encapsulating rapamycin have been demonstrated to mitigate immunogenicity of adeno-associated virus (AAV) gene therapy vectors, enhance levels of transgene expression, and enable redosing of AAV at moderate vector doses of 2 to 5E12 vg/kg. However, recent clinical trials have often pushed AAV vector doses 10-fold to 50-fold higher, with serious adverse events observed at the upper range. Here, we assessed combination therapy of ImmTOR with B cell-targeting drugs for the ability to increase the efficiency of redosing at high vector doses. The combination of ImmTOR with a monoclonal antibody against B cell activation factor (aBAFF) exhibited strong synergy leading to more than a 5-fold to 10-fold reduction of splenic mature B cells and plasmablasts while increasing the fraction of pre-/pro-B cells. In addition, this combination dramatically reduced anti-AAV IgM and IgG antibodies, thus enabling four successive AAV administrations at doses up to 5E12 vg/kg and at least two AAV doses at 5E13 vg/kg, with the transgene expression level in the latter case being equal to that observed in control animals receiving a single vector dose of 1E14 vg/kg. Similar synergistic effects were seen with a combination of ImmTOR and a Bruton's tyrosine kinase inhibitor, ibrutinib. These results suggest that ImmTOR could be combined with B cell-targeting agents to enable repeated vector administrations as a potential strategy to avoid toxicities associated with vector doses above 1E14 vg/kg.


  • Open Access

    Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease

    by Takashi Kei Kishimoto, Max Fournier, Alicia Michaud, Gina Rizzo, Christopher Roy, Teresa Capela, Natasha Nukolova, Ning Li, Liam Doyle, Fen-Ni Fu, et al.


  • Open Access

    Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia

    by Earl Sands, Alan Kivitz, Wesley DeHaan, Sheldon S. Leung, Lloyd Johnston, Takashi Kei Kishimoto

    Biologic drugs have transformed the standard of care for many diseases. However, many biologics induce the formation of anti-drug antibodies (ADAs), which can compromise their safety and efficacy. Preclinical studies demonstrate that biodegradable nanoparticles-encapsulating rapamycin (ImmTOR), but not free rapamycin, mitigate the immunogenicity of co-administered biologic drugs. Here we report the outcomes from two clinical trials for ImmTOR. In the first ascending dose, open-label study (NCT02464605), pegadricase, an immunogenic, pegylated uricase enzyme derived from Candida utilis, is assessed for safety and tolerability (primary endpoint) as well as activity and immunogenicity (secondary endpoint); in the second single ascending dose Phase 1b trial (NCT02648269) composed of both a double-blind and open-label parts, we evaluate the safety of ImmTOR (primary endpoint) and its ability to prevent the formation of anti-drug antibodies against pegadricase and enhance its pharmacodynamic activity (secondary endpoint) in patients with hyperuricemia. The combination of ImmTOR and pegadricase is well tolerated. ImmTOR inhibits the development of uricase-specific ADAs in a dose-dependent manner, thus enabling sustained enzyme activity and reduction in serum uric acid levels. ImmTOR may thus represent a feasible approach for preventing the formation of ADAs to a broad range of immunogenic biologic therapies.


  • Open Access

    Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles

    by Petr O. Ilyinskii, Alicia M. Michaud, Christopher J. Roy, Gina L. Rizzo, Stephanie L. Elkins, Teresa Capela, Aparajita C. Chowdhury, Sheldon S. Leung, Takashi K. Kishimoto

    Liver-directed AAV transgene expression is enhanced by ImmTOR nanoparticles.


  • Open Access

    Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice

    by Yao-Yun Fan, Lindsay B. Avery, Mengmeng Wang, Denise M. O'HAra, Sheldon Leung, Hendrik Neubert

    The neonatal Fc receptor (FcRn) is a homeostatic receptor responsible for prolonging immunoglobulin G (IgG) half-life by protecting it from lysosomal degradation and recycling it to systemic circulation. Tissue-specific FcRn expression is a critical parameter in physiologically-based pharmacokinetic (PBPK) modeling for translational pharmacokinetics of Fc-containing biotherapeutics. Using online peptide immuno-affinity chromatography coupled with high resolution mass spectrometry, we established a quantitative FcRn tissue protein expression profile in human FcRn (hFcRn) transgenic mice, Tg32 homozygous and hemizygous strains. The concentration of hFcRn across 14 tissues ranged from 3.5 to 111.2 pmole per gram of tissue. Our hFcRn quantification data from Tg32 mice will enable a more refined PBPK model to improve the accuracy of human PK predictions for Fc-containing biotherapeutics.


  • 2014 White Paper on Recent Issues in Bioanalysis: A Full Immersion in Bioanalysis (Part 3 – LBA and Immunogenicity)

    by Lauren Stevenson, Lakshmi Amaravadi, Heather Myler, Laura Salazar-Fontana, Boris Gorovits, Susan Kirshner, Li Xue, Fabio Garofolo, Stephen C Alley, Theingi Thway, et al.

    The 2014 8th Workshop on Recent Issues in Bioanalysis (8th WRIB), a 5-day full immersion in the evolving field of bioanalysis, took place in Universal City, California, USA. Close to 500 professionals from pharmaceutical and biopharmaceutical companies, contract research organizations and regulatory agencies worldwide convened to share, review, discuss and agree on approaches to address current issues of interest in bioanalysis. The topics covered included both small and large molecules, and involved LCMS, hybrid LBA/LCMS, LBA approaches and immunogenicity. From the prolific discussions held during the workshop, specific recommendations are presented in this 2014 White Paper. As with the previous years' editions, this paper acts as a practical tool to help the bioanalytical community continue advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2014 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 3) covers the recommendations for Large molecules bioanalysis using LBA and Immunogenicity. Part 1 (Small molecules bioanalysis using LCMS) and Part 2 (Hybrid LBA/LCMS, Electronic Laboratory Notebook and Regulatory Agencies' Input) were published in the Bioanalysis issues 6(22) and 6(23), respectively.


  • Protein-Based Matrix Interferences in Ligand-Binding Assays

    by Boris Gorovits, Jim McNally, Corinna Fiorotti, Sheldon Leung

    An adequate bioanalytical support for a typical biotherapeutic requires a number of assays, including those to measure drug concentration and to assess induction of specific immune responses. Ligand-binding assays are the most commonly used platform in bioanalysis of biotherapeutics. Ligand-binding assays are frequently designed to detect appropriate analytes in complex biological matrices with limited or no sample pretreatment steps. The complex composition of the test matrix is highly diverse and varies from normal to disease populations. Additional post-treatment changes are often observed, including induction of antidrug antibodies. Due to potential interaction of biological matrix components, for example, rheumatoid factors, heterophilic antibodies and human anti-animal antibodies, with the test analyte or assay reagents, ligand-binding assays are often subjected to various degrees of matrix interferences that lead to an erroneous under- or over-reporting of the analyte concentration. Impact of various matrix components and practical means designed to mitigate interferences are discussed in this Review.


  • Pharmacokinetics of anti-IL17A and anti-IL22 peptide–antibody bispecific genetic fusions in mice

    by Yulia Vugmeyster, Yiqun (Etran) Zhang, Xiaotian Zhong, Jill Wright, Sheldon S. Leung


  • One Mouse, One Pharmacokinetic Profile: Quantitative Whole Blood Serial Sampling for Biotherapeutics

    by Alison P. Joyce, Mengmeng Wang, Rosemary Lawrence-Henderson, Cynthia Filliettaz, Sheldon S. Leung, Xin Xu, Denise M. O’hara

    The purpose of this study was to validate the approach of serial sampling from one mouse through ligand binding assay (LBA) quantification of dosed biotherapeutic in diluted whole blood to derive a pharmacokinetic (PK) profile.


  • Automate it: ligand-binding assay productivity in a discovery bioanalytical setting

    by Sheldon S Leung, Elizabeth A Dreher

    In multiple industries, including the biopharmaceutical industry, automation is synonymous with increased productivity. Environments with high-throughput needs commonly employ automation for efficiency. However, in a discovery bioanalytical ligand-binding assay laboratory setting where the focus is not necessarily on sample analysis throughput, but instead on assay development and characterization, is automation applicable? Can automation enhance productivity when tasks are more customized than routine? In this Perspective we review the different categories of automation with ligand-binding assays with these questions in mind. In considering whether automation technology has progressed far enough to result in a positive return in investment in the discovery setting, the resource investment required to operate in this space was contrasted with the gain in productivity. In our opinion, technology advancements in automated technology platforms, and especially personal automation, have allowed these categories to strike the right balance for investment in the discovery laboratory setting.